OSE Immunotherapeutics - Lusvertikimab shines in Phase II UC trial
OSE Immunotherapeutics’ run of positive news continues with the announcement of encouraging data from the Phase II proof-of-concept CoTikiS study,...
311 Views
OSE Immunotherapeutics - Another partnership with expansion into CAR-T
OSE Immunotherapeutics has entered into a commercial and revenue sharing agreement with the Memorial Sloan Kettering Cancer Center (MSK), focused...
223 Views
OSE Immunotherapeutics - Strong momentum in deal flow
OSE Immunotherapeutic’s FY24 has started off with a series of major wins, significantly bolstering the company’s clinical pipeline and liquidity....
241 Views
OSE Immunotherapeutics - Another partnership win – Boehringer Ingelheim
OSE Immunotherapeutics has announced a considerable expansion of its partnership with Boehringer Ingelheim (BI), including the start of two new...
271 Views
OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle
OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is...
432 Views